Blueprint Genetics Plans to Boost Inherited Disease Panel Portfolio Next Year
Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territories, including the US.
The Helsinki-based firm started offering diagnostic gene panels for inherited cardiovascular disorders two years ago, using a targeted sequencing technology called OS-Seq that one of its co-founders developed as a postdoc at the Stanford Genome Technology Center.
Since then, business has taken off. According to CEO Tommi Lehtonen, Blueprint has tested almost 3,000 patients with its platform and has received samples from 122 hospitals in 17 countries, though its main markets are in Scandinavia, Canada, Australia, and Italy.